<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77431">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02140645</url>
  </required_header>
  <id_info>
    <org_study_id>1218.162</org_study_id>
    <nct_id>NCT02140645</nct_id>
  </id_info>
  <brief_title>Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy</brief_title>
  <official_title>Association of Clinical Covariates With Non-insulin Diabetes Medication Initiation Using Electronic Medical Records (EMR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to identify EMR-based clinical covariates and quantify their
      association with the prescribing of each specific type 2 diabetes (T2DM) medication under
      investigation. This will include an assessment of how well these covariates are captured
      through claims data proxies, and their potential to confound comparative research of T2DM
      medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Any note of albuminuria</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Any note of proteinuria</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure (diastolic), mmHg</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of smokers in following categories: current, past, never, not noted</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Alcohol consumption in following categories: none, moderate, high, not noted</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean BMI, kg/m2</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean duration of diabetes, years</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean HbA1c level, %</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean estimated glomerular filtration rate, ml/min</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Any note of cirrhosis, ascites, jaundice, hepatic failure, drug induced liver disease, hepatocellular disease</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Prior cancer</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean total cholesterol, mg/dL</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure (systolic), mmHg</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean ankle-brachial index</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Any note of diminished pulse at the foot</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Any note of neuropathy</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Any note of nephropathy</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Any note of retinopathy</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Prior stroke</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre-existing coronary artery disease, angina, myocardial infarction</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>History of gallstones</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>History of pancreatitis</measure>
    <time_frame>at least 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Glitazones</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-insulin injected</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulfonylurea</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        T2DM patients aged 18 or older, initiating antidiabetic treatment after at least 6 months
        of continuous enrollment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Dispensing of an oral or non-insulin injected hypoglycemic medication between May
             2011 and June 2012

          -  Diagnosis of type 2 diabetes mellitus

          -  Presence of electronic medical records (for the EMR-based subset)

        Exclusion criteria:

          -  Age &lt;18 at T2DM medication initiation

          -  Missing or ambiguous age or sex information

          -  At least one diagnosis of type 1 diabetes mellitus

          -  Less than 6 months enrolment in the database preceding the date of the first
             dispensing

          -  Prior use of the index drug
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1218.162.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>May 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
